Rate My Professor Gregory Moore

Associate Professor Gregory Moore, MBBS (Hons), PhD, FRACP, serves as Head of the Inflammatory Bowel Diseases (IBD) Unit at Monash Medical Centre in Melbourne and as Associate Professor (Research) in the Department of Medicine at Monash University, within the Centre for Inflammatory Disease at Monash Health. A graduate of Monash University with honors in medicine, he completed his gastroenterology training at Monash Medical Centre and St Vincent's Hospital Melbourne, followed by a basic science PhD at the University of Melbourne. In 2007, he founded the Inflammatory Bowel Diseases Unit at Monash Medical Centre, where he leads a multidisciplinary clinic delivering tertiary referral services across south-east Melbourne and rural Victoria. Balancing clinical duties with private practice, Moore coordinates multiple clinical trials, pursues active research agendas, supervises PhD and Bachelor of Medical Science students, and engages in undergraduate and postgraduate teaching.

Gregory Moore's research specializes in inflammatory bowel diseases, encompassing Crohn's disease and ulcerative colitis, with principal investigator roles in Phase 2 and 3 trials including tulisokibart for moderately to severely active Crohn’s disease, MK-7240 for ulcerative colitis, guselkumab for Crohn’s disease, upadacitinib extension in ulcerative colitis, and RVT-3101 for Crohn’s disease. His scholarly output includes 56 articles, 7 letters, 3 editorials, 3 systematic reviews, and additional contributions. Notable recent publications are '6-Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy' (2024, Internal Medicine Journal), 'Human Amniotic Epithelial Cell Transplantation is Safe and Well Tolerated in Patients with Compensated Cirrhosis: A First-in-Human Trial' (2024, Stem Cells Translational Medicine), 'Colonic cytomegalovirus DNA detection by polymerase chain reaction does not influence outcomes in inflammatory bowel disease and immunosuppressed cohorts' (2024, Internal Medicine Journal), 'Handgrip Strength Predicts Survival in Patients With Pancreatic Cancer' (2024, Pancreas), and 'Characteristics of the Kono-S anastomosis in Crohn's disease patients using intestinal ultrasound' (2024, European Journal of Gastroenterology & Hepatology). He chairs the Australian Inflammatory Bowel Diseases Association, sits on the board of Crohn's and Colitis Australia, and chairs its Medical and Scientific Committee, aligning his work with UN Sustainable Development Goal 3: Good Health and Well-being.